依维莫司治疗接受透析的转移性肾癌患者安全性和有效性的回顾性分析。
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
作者信息
Guida Annalisa, Masini Cristina, Milella Michele, Di Lorenzo Giuseppe, Santoni Matteo, Prati Veronica, Porta Camillo, Cosmai Laura, Donati Donatella, del Giovane Cinzia, Mighali Pasquale, Sabbatini Roberto
机构信息
Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.
AO Santa Maria Nuova, Reggio Emilia, Italy.
出版信息
Future Oncol. 2015;11(23):3159-66. doi: 10.2217/fon.15.256. Epub 2015 Nov 6.
AIMS
This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
PATIENTS & METHODS: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
RESULTS
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
CONCLUSION
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.
目的
本回顾性研究旨在调查依维莫司在转移性肾细胞癌（mRCC）和需要透析的终末期肾病患者中的安全性和有效性。
患者与方法
2009年11月至2012年12月，意大利6家机构中11例接受透析的mRCC患者在抗血管内皮生长因子（VEGF）治疗失败后接受依维莫司治疗。收集患者特征、安全性和结局。
结果
采用Kaplan-Meier法确定无进展生存期和总生存期。中位无进展生存期和总生存期分别为9.01个月和15.7个月。未报告意外不良事件。
结论
依维莫司在有肾功能损害或需要透析的终末期肾病的mRCC患者中似乎是安全的。需要更大规模的前瞻性研究来证实这些发现。
Zotero 插件